HDAC9 and neoplasm: Pre-clinical studies using cell lines from a variety of gynecologic [16–18] and other malignancies [19, 20] have demonstrated that natural and synthetic HDAC inhibitors can inhibit tumor cell growth in vitro and in vivo through cell cycle arrest as well as the induction of mitotic defects through histone mediated and histone independent interactions [15].